SafeBridge® Consultants Announces Improved Sensitivity for the Analysis of Naproxen Sodium Air Samples

Friday, May 17, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

SafeBridge Consultants announced today that its industrial hygiene analytical laboratory has successfully validated an industrial hygiene air sampling and analytical method with improved analytical sensitivity for measurement of naproxen sodium on filters. SafeBridge's laboratory can now quantify naproxen sodium collected on air sampling media at levels down to 5 picograms per filter, which is 10 times lower than methods available from other commercial laboratories.

MOUNTAIN VIEW, Calif., May 16, 2019 /PRNewswire-PRWeb/ -- SafeBridge Consultants, Inc. (SafeBridge), a Trinity Consultants

company headquartered in Mountain View, California, announced today that its industrial hygiene analytical laboratory has successfully validated an industrial hygiene air sampling and analytical method with improved analytical sensitivity for measurement of naproxen sodium on filters. SafeBridge's laboratory can now quantify naproxen sodium collected on air sampling media at levels down to 5 picograms per filter. This limit of quantification is ten (10) times lower than methods available from other commercial laboratories.

Naproxen sodium is used in the pharmaceutical, chemical, and nuclear industries for containment verification studies and as a surrogate for more potent or toxic compounds to assess potential worker exposure and for the performance of containment and control equipment during typical operations. Naproxen sodium has a number of advantages over traditional surrogates such as lactose. It has a high "dustiness quotient" presenting a more aggressive test than lactose and is considered a non-potent water-soluble material. Air monitoring surveys using naproxen sodium are conducted to replicate the performance of containment equipment under "real life" operating conditions.

With this improvement in sensitivity, naproxen sodium can now be measured at airborne concentrations as low as 0.1 nanograms per cubic meter (ng/m3) for 15 minute tasks. This creates an effective tool for organizations involved in handling hazardous materials in powder and liquid forms and to verify that controls can achieve the low Occupational Exposure Limits (OELs) and CPTs for highly toxic or potent compounds. According to SafeBridge's Kent Rader, "This development is important to pharmaceutical and chemical companies as well as containment and engineering control vendors to support safety in drug development activities."

SafeBridge's industrial hygiene laboratory is accredited by the American Industrial Hygiene Association – Lab Accreditation Program (AIHA-LAP) for the analysis of active pharmaceutical ingredients. The SafeBridge laboratory is able to apply the most sensitive techniques in the industry to detect potent drugs at very low concentrations in the workplace. The laboratory routinely develops methods and analyzes samples that contain biologically active pharmaceuticals such as steroid hormones, enzymes, peptide hormones, antibody drug conjugates (ADCs) and "cytotoxic" compounds. In addition, the laboratory conducts assessments of acceptable cleaning procedures to identify methods used to protect workers and to prevent product cross-contamination. The SafeBridge laboratory employs HPLC, LC/MS, and ELISA technologies to detect low concentrations of highly potent drugs on filters and swabs.

Background SafeBridge Consultants is the premier occupational health and safety consulting firm serving the pharmaceutical, biotechnology and fine chemical industries with offices in Mountain View, CA, New York, NY, Exton, PA and Liverpool and Ware, UK, and is a subsidiary of Trinity Consultants, Inc. based in Dallas, TX. SafeBridge has provided its Potent Compound Safety Triangle® of services comprising industrial hygiene, occupational toxicology, and industrial hygiene analytical chemistry to over 1200 business units worldwide and is a leader in recognizing, evaluating, and controlling exposures to potent active pharmaceutical ingredients and products.

For more information, contact: Kent Rader, Manager of Laboratory Analytical Business Development 650-961-4820 x 238 kent.rader(at)safebridge.com

 

SOURCE SafeBridge Consultants, Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store